Segulah Medical Acceleration

Navinci Diagnostics AB is a biotechnology company based in Uppsala, Sweden, specializing in biomolecular analysis for cancer and prenatal diagnostics. The company develops proprietary technology for detecting and quantifying proteins, their interactions, and modifications in various biological samples, including tissue, cells, and blood. Navinci offers a range of products, including universal kits for detecting proteins in cultured cells and fresh-frozen or formalin-fixed paraffin-embedded samples, as well as target-specific kits that are pre-optimized for specific variables. Additionally, Navinci provides in-house immunostaining and custom assay services that combine antibody-based proteomic technologies with fluorescence readouts, facilitating advanced research in human biology and drug development.

Signifier Medical Technologies Limited specializes in the manufacture and marketing of equipment designed to assist individuals with sleep disorders. Founded in 2015 and headquartered in London, the company offers a range of solutions, including sleep cycle monitoring, mouthpieces, and data tracking tools, marketed under the Snoozeal brand. The organization was established by Prof. Dr. Anshul Sama, who recognized the limitations of traditional treatments for sleep disorders, which often focused on alleviating symptoms rather than addressing the underlying causes. The company's innovative approach aims to improve patient comfort and sleep quality, moving beyond conventional devices that can disrupt sleep and are uncomfortable to wear. In May 2019, Snoozeal Limited rebranded as Signifier Medical Technologies Limited to reflect its broader mission in the field of sleep health.

SAGA Diagnostics AB is a Swedish company specializing in molecular genetic testing and services aimed at healthcare and biopharmaceutical sectors, as well as academic institutions. Founded in 2016 and based in Lund, SAGA focuses on personalized cancer genomics and disease monitoring. The company provides cutting-edge services such as cancer medicine, gene mutation analysis, and both tissue and non-invasive liquid biopsies, including blood samples. SAGA's proprietary technology enables the ultrasensitive quantification of circulating tumor DNA, achieving a detection limit of 0.001%. This advanced capability allows for the accurate detection of actionable mutations, patient stratification, and monitoring of treatment responses, thereby enhancing the management of cancer therapies and providing patients with greater peace of mind.

CytaCoat is a private Swedish company headquartered in the Karolinska Institutet Science Park in Solna, established by researchers from the Karolinska Institute and the Royal Institute of Technology. The company focuses on developing an innovative antibacterial coating technology for medical devices aimed at preventing healthcare-associated infections. Their proprietary polymer surface demonstrates effectiveness against several problematic pathogenic bacteria, addressing a significant challenge in healthcare. CytaCoat’s technology is designed to be stable under varying pH and ionic conditions, minimizing the release of potentially toxic components and preventing bacterial colonization without relying on antibiotics, which can lead to resistance. The company operates a fully equipped laboratory for microbiology evaluations and technology optimization, and it has established collaborations with clinical partners at the Karolinska University Hospital. Additionally, CytaCoat works with consultants specializing in regulatory affairs, clinical research, patenting, and specialized analyses to advance their product towards commercial viability and licensing opportunities.

Developer of a medical healthcare platform intended to make healthcare trusted, affordable, and accessible for everyone. The company's technology focuses on moving towards participation, prediction, and personalization of healthcare, enabling users to avail medical care at affordable rates.